GIANNONI, ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 21.279
AS - Asia 13.072
EU - Europa 11.927
SA - Sud America 2.834
AF - Africa 337
Continente sconosciuto - Info sul continente non disponibili 301
OC - Oceania 31
Totale 49.781
Nazione #
US - Stati Uniti d'America 20.076
SG - Singapore 4.750
RU - Federazione Russa 3.453
CN - Cina 3.152
IT - Italia 2.822
BR - Brasile 2.217
VN - Vietnam 1.816
GB - Regno Unito 1.767
BD - Bangladesh 952
HK - Hong Kong 921
DE - Germania 843
CA - Canada 840
UA - Ucraina 627
FR - Francia 441
SE - Svezia 436
IN - India 276
FI - Finlandia 273
DK - Danimarca 271
NL - Olanda 228
AR - Argentina 225
MX - Messico 220
IE - Irlanda 190
PL - Polonia 179
IL - Israele 177
TR - Turchia 160
ID - Indonesia 138
EC - Ecuador 127
ES - Italia 114
JP - Giappone 113
PK - Pakistan 111
IQ - Iraq 108
ZA - Sudafrica 107
AT - Austria 72
CO - Colombia 63
MA - Marocco 62
UZ - Uzbekistan 60
VE - Venezuela 57
AE - Emirati Arabi Uniti 43
CL - Cile 42
LT - Lituania 41
PH - Filippine 37
MY - Malesia 36
PY - Paraguay 33
SA - Arabia Saudita 32
KE - Kenya 31
EG - Egitto 28
TN - Tunisia 28
EU - Europa 27
NP - Nepal 26
PE - Perù 25
HN - Honduras 23
UY - Uruguay 23
CH - Svizzera 21
RO - Romania 21
JM - Giamaica 20
CR - Costa Rica 19
BE - Belgio 18
DZ - Algeria 18
AU - Australia 17
JO - Giordania 17
AZ - Azerbaigian 16
TH - Thailandia 15
BO - Bolivia 13
KG - Kirghizistan 13
KR - Corea 13
PT - Portogallo 13
DO - Repubblica Dominicana 12
GR - Grecia 12
NI - Nicaragua 12
PS - Palestinian Territory 12
CZ - Repubblica Ceca 10
GT - Guatemala 10
SV - El Salvador 10
TT - Trinidad e Tobago 10
NZ - Nuova Zelanda 9
PA - Panama 8
TW - Taiwan 8
BG - Bulgaria 7
ET - Etiopia 7
HU - Ungheria 7
KZ - Kazakistan 7
LY - Libia 7
OM - Oman 7
SI - Slovenia 7
AO - Angola 6
BH - Bahrain 6
CI - Costa d'Avorio 6
GE - Georgia 6
IR - Iran 6
MG - Madagascar 6
QA - Qatar 6
AL - Albania 5
BB - Barbados 5
CG - Congo 5
GY - Guiana 5
HR - Croazia 5
MD - Moldavia 5
MT - Malta 5
NO - Norvegia 5
RS - Serbia 5
Totale 49.402
Città #
Dallas 3.743
Singapore 2.379
Ashburn 1.607
San Jose 1.381
Beijing 1.245
Southend 907
Hong Kong 802
Chandler 734
Los Angeles 645
Moscow 597
Fairfield 585
Houston 550
Ho Chi Minh City 540
Woodbridge 469
Chicago 448
San Mateo 436
New York 430
Milan 428
Ann Arbor 422
Falls Church 406
Seattle 369
Hanoi 367
Cambridge 333
Jacksonville 333
Wilmington 324
The Dalles 310
Rome 289
Santa Clara 284
Council Bluffs 267
Ottawa 257
Buffalo 249
São Paulo 242
Boardman 231
Lauterbourg 224
Hefei 216
Dearborn 214
Dublin 188
Pisa 183
Salt Lake City 178
Portsmouth 170
Stevenage 164
Beauharnois 163
Orem 156
Tel Aviv 154
Warsaw 154
Munich 149
Dong Ket 147
Helsinki 142
London 141
Lawrence 132
Montreal 131
Brooklyn 121
Mexico City 113
Atlanta 101
Denver 101
Tokyo 99
Stockholm 92
Frankfurt am Main 90
Poplar 87
Chennai 85
Florence 84
Tampa 84
Toronto 84
Istanbul 77
Amsterdam 75
Johannesburg 73
Da Nang 72
Elk Grove Village 72
Montréal 72
Phoenix 72
Rio de Janeiro 71
Figino 67
Nuremberg 66
San Diego 64
Haiphong 62
Boston 57
Tashkent 55
Fremont 53
San Francisco 53
Columbus 51
Guayaquil 49
Manchester 49
Turin 49
Naples 48
Ankara 47
Bologna 47
Biên Hòa 45
Mumbai 44
Turku 44
Genoa 43
Brasília 41
Lappeenranta 40
Redwood City 40
Belo Horizonte 39
Miami 38
Paris 37
Quito 37
Dongguan 36
Guangzhou 36
Baghdad 35
Totale 28.712
Nome #
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.706
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 623
A cross-correlational analysis between electroencephalographic and end-tidal carbon dioxide signals: Methodological issues in the presence of missing data and real data results 513
Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease 454
Prognostic Significance of Central Apneas Throughout a 24-Hour Period in Patients With Heart Failure 401
A simple echocardiographic score to rule out cardiac amyloidosis 391
A simple echocardiographic score to rule out cardiac amyloidosis 366
"Targeting and Treating Apneas" in "The Breathless Heart: Apneas in Heart Failure" 358
A simple method for measuring baroreflex sensitivity holds prognostic value in heart failure 352
"To Breathe, or Not to Breathe: That Is the Question" in "The Breathless Heart: Apneas in Heart Failure" 347
Central sleep apnea and cardiovascular disease state-of-the-art 344
[Central apneas and cardiovascular diseases] 340
An open computational toolbox to analyze multi- and single-unit sympathetic nerve activity in microneurography 338
Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment? 333
Adaptive servo-ventilation therapy does not favourably alter sympatho-vagal balance in sleeping patients with systolic heart failure and central apnoeas: Preliminary data 332
Abnormal hyperventilation in patients with hepatic cirrhosis: Role of enhanced chemosensitivity to carbon dioxide. 331
Prediction of the chemoreflex gain by common clinical variables in heart failure 331
Etiology, clinical presentation, and management of left main coronary artery aneurysms 330
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 330
Treating chemoreflex in heart failure: modulation or demolition? 327
Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? 319
A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance 318
Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure 317
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 316
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 314
Adrenergic activation in heart failure: blockade or rebalance? 313
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 306
Eligibility for vericiguat in a real‐world, contemporary heart failure population 304
After the SERVE-HF Trial, Is There Still a Need for Treatment of Central Apnea? 304
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 303
Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure 301
Glycosylated haemoglobin is associated with neurohormonal activation and poor outcome in chronic heart failure patients with mild left ventricular systolic dysfunction 300
An analysis of fMRI signal during voluntary breath hold and carbon dioxide challenge: physiological correction and modeling issues 297
Screening the health status of people working in a university 295
AEROBIC TRAINING DECREASES AORTIC STIFFNESS IN PATIENTS WITH HEART FAILURE 293
Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential 292
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 290
How to take arms against central apneas in heart failure 285
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 285
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 282
Diaphragm function does not independently predict exercise intolerance in patients with precapillary pulmonary hypertension after adjustment for right ventricular function 281
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 280
Effects of central apneas on sympathovagal balance and hemodynamics at night: impact of underlying systolic heart failure 277
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 275
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 271
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 271
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 269
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 268
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 266
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 265
Effects of nasal high flow on sympathovagal balance, sleep, and sleep-related breathing in patients with precapillary pulmonary hypertension 265
Cardiac magnetic resonance findings and prognosis in type 1 myotonic dystrophy 263
Models of BOLD Signal Change in Breath Hold Studies and CO2 Challenges: Methodological Issues and Interpretation 263
Improved survival in limited scleroderma-related pulmonary artery hypertension 262
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 261
B-type natriuretic peptide secretion following scuba diving 261
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 261
A Novel Homozygous Mutation of the Desmoplakin Gene With Biventricular Arrhythmogenic Cardiomyopathy 261
Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones 260
Valve disease in cardiac amyloidosis: an echocardiographic score 259
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 259
null 258
APAP therapy does not improve impaired sleep quality and sympatho-vagal balance: a randomized trial in patients with obstructive sleep apnea and systolic heart failure 258
null 258
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 255
Correlational analysis of electroencephalographic and end-tidal carbon dioxide signals during breath-hold exercise 255
null 253
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease 253
A Novel Workflow for Electrophysiology Studies in Patients with Brugada Syndrome 252
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 250
Mapping dependencies of BOLD signal change to end-tidal CO2: Linear and nonlinear modeling, and effect of physiological noise correction 249
An atypical case of cardiac amyloidosis. 248
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register 247
Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance 247
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 244
Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension 244
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 244
Heart Failure Results in Inspiratory Muscle Dysfunction Irrespective of Left Ventricular Ejection Fraction 242
Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. 241
High-risk NSTEMI due to subclavian artery atherothrombosis in a prior coronary artery bypass graft patient 240
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 240
Renin profiling predicts neurohormonal response to sacubitril/valsartan 240
Role of Imaging in Cardiomyopathies 239
Effects of hyperventilation length on muscle sympathetic nerve activity in healthy humans simulating periodic breathing 239
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 238
Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic Heart Failure 238
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 238
Cheyne-Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea 237
Changes in chemoreflex characteristics following acetazolamide administration in patients with chronic heart failure and Cheyne Stokes respiration 236
Autonomic and respiratory consequences of altered chemoreflex function: clinical and therapeutic implications in cardiovascular diseases 235
A scoping review of machine learning models to predict risk of falls in elders, without using sensor data 234
Ld-EEG Effective Brain Connectivity in Patients With Cheyne-Stokes Respiration 234
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry 230
Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. 230
Inspiratory muscle dysfunction and restrictive lung function impairment in congenital heart disease: Association with immune inflammatory response and exercise intolerance 230
Impact of Simulated Hyperventilation and Periodic Breathing on Sympatho-Vagal Balance and Hemodynamics in Patients with and without Heart Failure 230
On the Use of Linear-Modelling-based Algorithms for Physiological Noise Correction in fMRI Studies of the Central Breathing Control 229
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 228
null 228
Diagnosis of preclinical /mild heart failure with B-type natriuretic peptides: compariosn betwwen BNP and NT-proBNP immunoassay methods 227
Totale 29.897
Categoria #
all - tutte 242.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 242.121


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.184 0 385 113 278 71 43 239 431 151 247 55 171
2022/20231.643 133 154 83 209 220 243 17 143 253 32 81 75
2023/20241.162 107 34 280 90 37 88 80 49 30 39 39 289
2024/202510.696 65 80 466 207 596 585 1.383 2.351 871 949 1.993 1.150
2025/202626.160 1.363 4.006 2.931 3.638 2.944 1.612 2.391 1.058 1.413 1.557 1.726 1.521
2026/2027843 760 83 0 0 0 0 0 0 0 0 0 0
Totale 49.781